Once-weekly HIV pill shows promise in Phase 3 clinical trial

A new once-weekly HIV pill has shown encouraging results in a Phase 3 trial, matching the effectiveness of daily treatment. The tablet combines Merck's islatravir and Gilead's lenacapavir and could become the first complete once-weekly oral HIV treatment if approved. Further monitoring will assess its long-term safety.